Smoldering Multiple Myeloma – to treat or not to treat?
7 helmikuun, 2024Smoldering multiple myeloma (SMM) is an intermediate condition that lies between Monoclonal gammopathy of undetermined significance (MGUS) and active multiple…MGRS- Monoclonal Gammopathy of Renal Significance
26 lokakuun, 2023Monoclonal gammopathy of renal significance (MGRS) is a hemato-nephrological term referring to a heterogeneous group of kidney disorders characterized by…Extramedullar disease in Multiple Myeloma
7 heinäkuun, 2023Experts call for a better understanding of how myeloma cells grow and thrive and the biology of extramedullary tumors in…Recent findings in MGUS
15 huhtikuun, 2023Professor Kristinsson will bring us up to date on recent understandings of the MGUS condition, what symptoms we as health…Mental health during and after cancer treatment
14 joulukuun, 2022In this episode we discuss the severe impact a physical illness can have on mental health.MRD as primary endpoint
29 marraskuun, 2021With help from Professor Ola Landgren, we will look into the crystal ball and discover what the future may hold…Minimal Residual Disease (MRD) – Cost vs Benefit
28 lokakuun, 2021Should MRD always be treated? Will it give a better outcome for the patient? And do the benefits outweigh the…